Clinical trials: Conjunctival Diseases
Allergic Conjunctivitis
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
- Trial name
- NCT04207736
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Keratoconjunctivitis Sicca, Dry Eye Disease
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye.
- Trial name
- OPUS-1 (NCT01421498)
- Testing
- Lifitegrast
- Where
- 13 sites in United States
- Volunteers
- 588 people
- Sponsor
- Shire
Hypersensitivity, Allergic Rhinitis
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing…
- Conditions
- Hypersensitivity, Allergic Rhinitis, Allergic Conjunctivitis, Seasonal Allergy
- Trial name
- NCT01731249
- Testing
- Birch pollen allergen extract
- Where
- 11 sites in Czechia, Denmark and 9 more
- Volunteers
- 574 people
- Sponsor
- Stallergenes Greer
Bacterial Conjunctivitis, Acute
Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical…
- Trial name
- NCT01227863
- Testing
- MAXINOM®, Maxitrol®
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Azidus Brasil
Keratoconjunctivitis Sicca
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50…
- Trial name
- Emerald (NCT02688556)
- Testing
- cyclosporine, vehicle of OTX-101
- Where
- 3 sites in United States
- Volunteers
- 745 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Allergic Conjunctivitis
A Six-Week Safety Study of an Investigational Ophthalmic Solution
The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.
- Trial name
- NCT01698814
- Testing
- AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Keratoconjunctivitis Sicca
Effect of Controlled Adverse Environment (CAE) on Tear Film Stability
The purpose of this study is to evaluate the effect of the controlled adverse environment (CAE) on Mean Break-Up Area in subjects diagnosed with Dry Eye Syndrome.
- Trial name
- NCT01547936
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- ORA, Inc.
Dry Eye, Dry Eye Syndromes
Tear Production by Nasal Neurostimulation Compared to Active Control
This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones…
- Conditions
- Dry Eye, Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Trial name
- NCT02970799
- Testing
- Intranasal Neurostimulator
- Volunteers
- 27 people
- Sponsor
- Oculeve, Inc.
Allergic Conjunctivitis
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
- Trial name
- NCT03494504
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 318 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT04050865
- Testing
- Dexamethasone, 0.4mg
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Ocular Therapeutix, Inc.
Allergic Conjunctivitis
AGN-229666 for the Treatment of Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
- Trial name
- NCT01754766
- Testing
- AGN-229666, vehicle of AGN-229666
- Where
- Japan
- Volunteers
- 90 people
- Sponsor
- Allergan
Seasonal Allergic Rhinitis
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
The objective of this study is to assess the effect of grass pollen extract SLIT tablets on the Rhinoconjunctivitis Total Symptom Score (RTSS) of the six rhinoconjunctivitis symptoms in response to grass pollen challenge after…
- Trial name
- NCT00619827
- Testing
- 300 IR grass pollen allergen extract tablet
- Where
- Austria
- Volunteers
- 89 people
- Sponsor
- Stallergenes Greer
Allergic Conjunctivitis
A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.
- Trial name
- NCT01363713
- Testing
- DE-114 ophthalmic solution
- Where
- Japan
- Volunteers
- 130 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Dry Eye Syndrome
Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients
The study will assess the safety, tolerability and feasibility of Lacrima investigational medical device to treat dry eye patients
- Trial name
- NCT01957670
- Testing
- Lacrima medical Prototypes
- Where
- Israel
- Sponsor
- Lacrima Medical LTD
Seasonal Allergic Conjunctivitis
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
Medications available for the treatment of seasonal allergic conjunctivitis include antihistamines. These medicines block the release of histamine, a substance in the body that is released when an allergic reaction occurs.
- Trial name
- NCT00133627
- Testing
- Ketotifen
- Where
- China
- Volunteers
- 229 people
- Sponsor
- Novartis
Allergic Rhinitis, Conjunctivitis
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU)…
- Trial name
- NCT05430919
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 3 sites in Canada
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Allergic Rhinitis, Conjunctivitis
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
- Trial name
- NCT04709575
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 353 people
- Sponsor
- Regeneron Pharmaceuticals
Keratoconjunctivitis, Vernal
Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis
To assess the clinical and biological efficacity of preservative free NAAGA eyes drops in vernal keratoconjunctivitis
- Trial name
- NCT00357019
- Testing
- N-acetyl-aspartyl-glutamate (NAAXIA Sine)
- Sponsor
- Laboratoires Thea
Keratoconjunctivitis Sicca
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02121301
- Testing
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mitotech, SA
Allergy, Rhinitis
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
Efficacy and Safety from a high-dosed sublingual grass pollen preparation
- Conditions
- Allergy, Rhinitis, Conjunctivitis
- Trial name
- ALLEGRA6 (NCT00623701)
- Testing
- Allerslit forte
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- Allergopharma GmbH & Co. KG